John Hardy

Prof Sir John Hardy

Group Leader

Harnessing genetics to build a better understanding of dementia

Condition

Alzheimer's disease, Parkinson's disease

Topics

Genetics

Biography

Prof Sir John Hardy is a world-leading neurogeneticist in the field of neurodegenerative diseases, receiving numerous accolades that include the Breakthrough Prize in Life Sciences, the Brain Prize, election as a Fellow of the Royal Society and, in 2022, a knighthood for his contributions to science and health. In 1991, Hardy's team uncovered the first mutation directly implicated in Alzheimer's disease leading to the formulation of the highly influential 'amyloid-cascade' hypothesis. His extensive body of work in genetics will be built upon in this UK DRI programme, where the team will unravel pathogenic networks in neurodegenerative disease.

News

Key publications

Cell reports
Published
Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease
Authors
Elena Eubanks, Katelyn VanderSleen, Jiya Mody, Neha Patel, Benjamin Sacks, Mahsa Darestani Farahani, Jinying Wang, Jordan Elliott, Nora Jaber, Fulya Akçimen, Sara Bandres-Ciga, Fadel Helweh, Jun Liu, Sanjana Archakam, Robert Kimelman, Bineet Sharma, Philip Socha, Ananya Guntur, Yiming Huang, Nagendran Ramalingam, Elyse Guadagno, Tim Bartels, Ulf Dettmer, M Maral Mouradian, Amir Houshang Bahrami, Wei Dai, Jean Baum, Zheng Shi, John Hardy, Eleanna Kara
Increased burden of rare risk variants across gene expression networks predisposes to sporadic Parkinson's disease
Neurobiology of aging
Published
Presenilin 1 hemizygosity has no overt deleterious phenotypic outcomes in sheep: Potential implications for therapeutic targets in Alzheimer's disease
Authors
Natasha E Mckean, Jun Liu, Skye R Rudiger, Jennifer M Kelly, Clive McLaughlan, Paul J Verma, John Hardy, James F Gusella, Henrik Zetterberg, Suzanne J Reid, Renee H Handley, Klaus Lehnert, Greg T Sutherland, Amanda Heslegrave, Elena Veleva, Rhiannon Laban, John F Pearson, Simon C Bawden, Russell G Snell
Presenilin 1 hemizygosity has no overt deleterious phenotypic outcomes in sheep: Potential implications for therapeutic targets in Alzheimer's disease
medRxiv : the preprint server for health sciences
Published
Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson's disease
Authors
Manuela Mx Tan, Hirotaka Iwaki, Sara Bandres-Ciga, Yuri Sosero, Maryam Shoai, Kathrin Brockmann, Nigel M Williams, Roy N Alcalay, Jodi Maple-Grødem, Guido Alves, Ole-Bjørn Tysnes, Peggy Auinger, Shirley Eberly, Peter Heutink, David K Simon, Karl Kieburtz, John Hardy, Caroline H Williams-Gray, Donald G Grosset, Jean-Christophe Corvol, Ziv Gan-Or, Mathias Toft, Lasse Pihlstrøm
Polygenic scores for disease risk are not associated with clinical outcomes in Parkinson's disease

Hardy Lab

Explore the work of the Hardy Lab, harnessing genetics to build a better understanding of dementia

 
Hardy Lab